Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace Hotel. CEO Gail McIntyre and CFO Rudy Howard will represent the company. The presentation will be available for viewing on September 12, 2022, at 7:00 am ET, with a 90-day archived replay accessible on the company’s website. Aravive is focused on targeted therapeutics for metastatic disease, with its lead candidate, batiraxcept, in multiple clinical trials and having received Fast Track Designation from the FDA.

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the H.C. Wainwright 24^th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace Hotel, New York, N.Y.

The Company’s presentation will be available for viewing on September 12, 2022, at 7:00 am ET. An archived replay of the webcast will be available for 90 days following the webcast on the Events & Presentations page of www.aravive.com. Aravive will also participate in one-on-one meetings at the conference.

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com. 

Contact:
Luke Heagle
Real Chemistry
(910) 619-5764
ir@aravive.com

FAQ

What is the date of the H.C. Wainwright Global Investment Conference for Aravive?

The conference will be held from September 12-14, 2022.

Who will represent Aravive at the investment conference?

CEO Gail McIntyre and CFO Rudy Howard will represent Aravive.

When will Aravive's presentation be available for viewing?

The presentation will be available on September 12, 2022, at 7:00 am ET.

What is batiraxcept, the product candidate of Aravive?

Batiraxcept is an ultra-high affinity decoy protein that targets GAS6 to inhibit metastasis and tumor growth.

What designations has batiraxcept received?

Batiraxcept has received Fast Track Designation from the FDA and Orphan Drug Designation from the European Commission.

What clinical trials is Aravive currently conducting?

Aravive is conducting trials for batiraxcept in ovarian cancer, renal cell carcinoma, and pancreatic adenocarcinoma.